JNJ's regulatory filing seeks the FDA's approval for TAR-200, a drug-device combination for treating certain bladder cancer ...

They were used on five patients, and four of them are now either in remission or cancer-free. Read more at straitstimes.com.

J&J acquired rights to TAR-200 when it bought privately-owned biotech Taris for an undisclosed sum in 2019, and has big sales ...

An FDA application for TAR-200 to treat BCG-unresponsive high-risk non-muscle-invasive bladder cancer is under real-time ...

The Ministry of Health has conceded a shortage of vaccines for newborns. The Director General for Health Patrick Amoth on ...

ImmunityBio, Inc. , a leading immunotherapy company, today announced significant progress in its ongoing discussions with the U.S. Food and Drug Administration (FDA) regarding three areas of its ...

However, Kenya Medical Supplies Agency (Kemsa) CEO Waqo Erjesa said on Wednesday they have sufficient stocks of the HIV ...